Interrelation of tumor infiltrating lymphocyte subpopulations with clinical and pathomorphological features of a breast cancer

Cover Page

Cite item

Full Text

Abstract

Levels of intratumoral lymphocytes have direct interrelations with clinical, morphological and biological characteristics of tumor. Rates of CD4+lymphocytes rise in a process of increase of tumor size. At the same time, content of intratumoral CD4+CD25+ lymphocytes is maximal at small size tumors. In the absence of metastases of a breast cancer in the regional lymph nodes are noted a higher content of activated (HLA-DR+) intratumoral T-lymphocytes (CD3, CD4, CD8), which is represented in a higher levels of HLA-DR+CD45+ lymphocytes in patients with a lack of metastasis in comparison with patients, who has metastasis. In case of II and III grade of breast cancer malignancy the percent of intratumoral lymphocytes is higher, in comparison to I grade malignancy. The rate of intratumoral lymphocytes as well as activated T-cells (CD3) and T-helpers (CD4) is higher in stage I of breast cancer, then in II–III stages. The number of intratumoral CD3+ T-lymphocytes and CD8+ cells is higher in tumors with low level of Ki-67+ proliferated cells. Authentically higher content of activated T-cells and activated CD4+ lymphocytes is noted in HER-2 / neu-negative cases. Higher content of CD4+CD3+ T-lymphocytes was noted in 2–3 scores of HER-2 / neu than negative HER-2 / neu status. At an infiltrative ductal cancer authentically higher levels of infiltration of a tumor are revealed by the lymphocytes, activated T-cells and activated T-killers CD3+CD8+. Tumor infiltration levels in luminal A cancer are 5 times higher, then in luminal B (10,5 and 2,2 % correspondingly). At the same time, luminal B subtype is characterized by higher tumor infiltration of T-lymphocytes (81 and 70 %).

About the authors

O. A. Beznos

N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia

Author for correspondence.
Email: beznos.olga@gmail.com
Russian Federation

D. A. Burov

A.I. Evdokimov Moscow State Medical and Stomatological University, Ministry of Health of Russia

Russian Federation

V. Yu. Sel’chuk

N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia;
A.I. Evdokimov Moscow State Medical and Stomatological University, Ministry of Health of Russia

Russian Federation

I. K. Vorotnikov

A.I. Evdokimov Moscow State Medical and Stomatological University, Ministry of Health of Russia

Russian Federation

V. V. Timoshenko

N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia

Russian Federation

T. A. Grigor’eva

A.I. Evdokimov Moscow State Medical and Stomatological University, Ministry of Health of Russia

Russian Federation

Ya. V. Vishnevskaya

N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia

Russian Federation

N. N. Tupitsyn

N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia

Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c)



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 36991 от  21.07.2009.